US 11,731,976 B2
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator
Andrew Mark Griffin, L'lle Bizard (CA); Brian Edward Marron, Ada, MI (US); and Gabriel Martinez Botella, Wayland, MA (US)
Assigned to PRAXIS PRECISION MEDICINES, INC., Boston, MA (US)
Filed by Praxis Precision Medicines, Inc., Cambridge, MA (US)
Filed on Mar. 26, 2021, as Appl. No. 17/214,343.
Application 17/214,343 is a continuation of application No. 17/102,586, filed on Nov. 24, 2020, granted, now 11,014,931.
Application 17/102,586 is a continuation of application No. PCT/US2019/034653, filed on May 30, 2019.
Claims priority of provisional application 62/738,508, filed on Sep. 28, 2018.
Claims priority of provisional application 62/677,903, filed on May 30, 2018.
Prior Publication US 2022/0024930 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61P 23/00 (2006.01); A61P 25/08 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 23/00 (2018.01); A61P 25/08 (2018.01); C07D 471/04 (2013.01); C07B 2200/13 (2013.01)] 30 Claims
 
1. A method for modulating sodium ion channel activity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the compound:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.